Regeneron sees strong Eylea sales; financials beat expectations

10 February 2015

US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) today announced financial results for the fourth quarter and full year 2014, showing that total revenues for the quarter increased 31% to $802.3 million, above the average analyst estimate of $781.52 million.

Total revenues include collaboration payments from German pharma major Bayer (BAYN: DE) and French peer Sanofi (Euronext: SAN). Sales in the USA of the company’s only marketed product, the ophthalmic treatment Eylea (aflibercept) – which is sold outside the USA by Bayer -came in at $518 million, a rise of 29%.

Net profit rose 13% to $110.2 million, or $0.96 per share (+12%), in the fourth quarter. Excluding special items, Regeneron earned $2.79 per share, (+25%) but below the average analyst estimate of $2.82 per share, according to Thomson Reuter.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK